Inactive Instrument

Novoheart Holdings Inc.

Equities

NVH

CA67011V1076

Biotechnology & Medical Research

Novoheart Holdings Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2018

November 22, 2018 at 08:21 pm

Novoheart Holdings Inc. announced unaudited consolidated earnings results for the first quarter ended September 30, 2018. For the quarter, the company reported loss from operation of CAD 1,975,684 against CAD 1,083,466 a year ago. Net loss for the quarter was CAD 1,949,801 or CAD 0.02 per basic and diluted share against CAD 6,272,569 or CAD 0.58 per basic and diluted share a year ago.

Latest news about Novoheart Holdings Inc.

Novoheart Holdings Inc.(TSXV:NVH) dropped from S&P/TSX Venture Composite Index	20-11-23	CI
Novomed Limited completed the acquisition of 12.6% stake in Novoheart Holdings Inc..	20-11-17	CI
Novomed Limited entered into a definitive arrangement agreement to acquire 12.6% stake in Novoheart Holdings Inc. for CAD 12.6 million.	20-09-14	CI
Novoheart Holdings Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-31	CI
Novoheart Holdings Inc. Announces Directorship Appointments	20-05-19	CI
Novoheart Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-19	CI
Novoheart Holdings Inc. Announces Change of its Fiscal Year-End to December 31, from June 30	20-03-11	CI
Novoheart Announces the Completion of a Research and Development Contract Sponsored by a Top 10 Global Pharma	20-01-21	CI
Novoheart Announces an Exclusive Licensing Agreement with Harvard University's Office of Technology Development	19-12-16	CI
Novoheart Announces Change of Fiscal Year-End	19-11-29	CI
Novoheart Holdings Inc. Announces Management Changes	19-11-29	CI
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca	19-11-26	CI
Novoheart Holdings Inc. Reports Earnings Results for the First Quarter Ended September 30, 2019	19-11-18	CI
Novoheart Holdings Inc. Demonstrates Advanced Capabilities for Drug Screening as Well as Disease Modeling Which Can Lead to Safer Drugs with Better Efficacy, According to New Research	19-09-09	CI
Novoheart Holdings Inc. Reports Earnings Results for the Full Year Ended June 30, 2019	19-09-05	CI
Novoheart Holdings Inc. completed the acquisition of Xellera Therapeutics Limited from Ruby Fame Limited, Marine Bridge International Limited and Ronald Li.	19-06-27	CI
Novoheart Holdings Inc. Announces Executive Changes	19-06-17	CI
Novoheart Holdings Inc. entered into a definitive agreement to acquire Xellera Therapeutics Limited from Ruby Fame Limited, Marine Bridge International Limited and Ronald Li for CAD 32.6 million.	19-05-27	CI
Novoheart Holdings Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2019	19-05-17	CI
Novoheart Holdings Inc.(TSXV:NVH) added to S&P/TSX Venture Composite Index	19-04-22	CI
Novoheart Holdings Inc. Announces Board Appointments	19-03-01	CI
Novoheart Holdings Inc. Reports Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended December 31, 2018	19-03-01	CI
Novoheart Holdings Inc. Announces Executive Changes	19-01-07	CI
Novoheart Holdings Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2018	18-11-22	CI
Novoheart Enters into A Service Agreement with Xellera Therapeutics Limited	18-10-31	CI

Chart Novoheart Holdings Inc.

Duration

Period

More charts

Company Profile

Novoheart Holdings Inc is a Canada-based holding company. The Company, through its subsidiary, provides, discovers and develops heart therapeutics. Novoheart's scientific team has pioneered a range of bioengineering technologies collectively known as the MyHeart platform, including first human mini-heart ânovoHeartâ that is capable of fully capable of pumping and ejecting fluid. It is currently partnering with a pharmaceutical company to develop human heart tissues and chambers that carry a hereditary neurodegenerative disease. It is anticipated that the pharmaceutical company will be able to use the developed pathological tissues as a unique drug discovery and drug screening platform for effective therapies targeting the heart-associated issues of this specific disease. Novoheart is currently completing the build out a large commercial laboratory in Asia to enable it to service additional potential commercial partnerships, which are under discussion.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-0.29%	21.78B
GENMAB A/S	-9.28%	18.09B
WUXI APPTEC CO., LTD.	-41.70%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs